Text Size

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier:
NCT01492647
First received: December 13, 2011
Last updated: February 18, 2013
Last verified: February 2013
History of Changes
  Purpose

The purpose of this study is to evaluate the safety and tolerability of JNJ 10229570-AAA after a single topical application of JNJ 10229570-AAA 1.2% and 3.6% cream in Japanese participants with acne.


Condition Intervention Phase
Acne Vulgaris
 Drug: JNJ 10229570-AAA 1.2%
Drug: JNJ 10229570-AAA 3.6%
Drug: Color-matched vehicle containing 0 mg of JNJ 10229570-AAA
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blinded, Single Topical Dose Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Subjects With Acne Vulgaris

Resource links provided by NLM:

MedlinePlus related topics: Acne
U.S. FDA Resources

Further study details as provided by Janssen Pharmaceutical K.K.:

Primary Outcome Measures:
  • Topical Dermatological Assessment (Scores on Scales) [ Time Frame: Days 1-7 ] [ Designated as safety issue: No ]
    The Topical Dermatological Assessment is based on the 3 to 4-point Cutaneous Irritation Grading Scales that assess the level of Erythema, Dryness, Peeling/Scaling, Burning/Stinging, and Itching from 0 (no reaction) to 3 or 4 (strong reaction). In addition, the assessment observes and records any pigmentation change that may occur on the skin after the intervention.


Secondary Outcome Measures:
  • Plasma M1 concentrations [ Time Frame: 12 time points up to 72 hours ] [ Designated as safety issue: No ]
  • PK parameters [ Time Frame: 12 time points up to 72 hours ] [ Designated as safety issue: No ]
    PK parameters of JNJ-10229570-AAA, as measured by AUC, Cmax and tmax


Enrollment: 18
Study Start Date: August 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: JNJ 10229570-AAA 1.2% Drug: JNJ 10229570-AAA 1.2%
One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Drug: Color-matched vehicle containing 0 mg of JNJ 10229570-AAA
One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
Experimental: JNJ 10229570-AAA 3.6% Drug: JNJ 10229570-AAA 3.6%
One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Drug: Color-matched vehicle containing 0 mg of JNJ 10229570-AAA
One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.

Detailed Description:

This is a randomized (drug assigned by chance like flipping a coin), double blinded (neither physician nor patient knows the name of the assigned drug), single dose ascending study of JNJ 10229570-AAA in Japanese participants with acne. The study will evaluate the safety and pharmacokinetics ([PK] how the drug is absorbed in the body, how it is distributed within the body and removed from the body over time) of M1 (active metabolite) in a total of eighteen (18) participants enrolled in the study, nine (9) in each group. Each participant will receive JNJ 10229570-AAA at 1.2%, 3.6% or vehicle in a cream formulation as a 2.5 mL application, to the face, neck, shoulders, chest and upper back areas. The investigational product will be washed off after the blood sampling at 24 hours after application. Safety and tolerability will be evaluated throughout the study and a topical dermatological assessment will be done by the dermatologists. The total duration of the study will be maximum 35 days.

  Eligibility

Ages Eligible for Study:   20 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have Acne vulgaris, presenting at least inflammatory lesion on the face
  • Body mass index between 18.0 and 30.0 kg/m2 (inclusive), and body weight not less than 50 kg (man) or 45 kg (woman)
  • Blood pressure between 90 and 140 mmHg systolic (inclusive), and no higher than 90 mmHg diastolic
  • Electrocardiogram (ECG) consistent with normal cardiac conduction and function
  • Non-smoker
  • Adequate contraception method for both men and women. If a woman, must have a negative pregnancy test
  • Signed an informed consent document

Exclusion Criteria:

  • History of or current clinically significant medical illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Clinically significant abnormal values for hematology, biochemistry or urinalysis
  • Clinically significant abnormal physical examination, vital signs or ECG - Use of any prescription or nonprescription medication within 14 days before the study treatment
  • History of drug or alcohol abuse within the past 5 years
  • Drug allergy or drug hypersensitivity
  • Blood donation, depending on the volume of blood collection
  • Positive test for human immunodeficiency virus (HIV), hepatitis B or C, or syphilis
  • Dermatological disease at application site
  • Photosensitivity
  • Exposure to excessive or chronic ultraviolet (UV) radiation (i.e., sunbathing, tanning salon use, phototherapy) within 4 weeks prior to study treatment or planned during the study period
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01492647

Locations
Japan
Fukukoka, Japan
Hakata, Japan
Sponsors and Collaborators
Janssen Pharmaceutical K.K.
Investigators
Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial Janssen Pharmaceutical K.K.
  More Information

No publications provided

Responsible Party: Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier: NCT01492647     History of Changes
Other Study ID Numbers: CR018673, 10229570-JPN-02
Study First Received: December 13, 2011
Last Updated: February 18, 2013
Health Authority: Japan: Pharmaceuticals and Devices Agency

Keywords provided by Janssen Pharmaceutical K.K.:
Acne vulgaris
JNJ 10229570-AAA
Japanese patients
Topical treatment

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Facial Dermatoses
Sebaceous Gland Diseases

ClinicalTrials.gov processed this record on May 16, 2013